Table 1.
Baseline characteristics of the analyzed population.
| Placebo group (n = 15) | Bumetanide group (n = 15) | Total (n = 30) | ||||
|---|---|---|---|---|---|---|
| Age (years, SD) | 8.7 (3.1) | 10.9 (2.5) | 9.8 (3.0) | |||
| Sex (%) Male | 10 (66.7) | 12 (80.0) | 22 (73.3) | |||
| Female | 5 (33.3) | 3 (20.0) | 8 (26.7) | |||
| IQ (SD) | 99.5 (25.3) | 98.9 (24.0) | 99.2 (24.2) | |||
| Medication use (%) | Prior | During trial | Prior | During trial | Prior | During trial |
| None | 7 (46.7) | 11 (73.3) | 9 (60.0) | 12 (80.0) | 16 (53.3) | 23 (76.7) |
| AP | 1 (6.7) | 1 (6.7) | 1 (6.7) | 2 (13.3) | 2 (6.7) | 3 (10.0) |
| AED | 5 (33.3) | 2 (13.3) | 1 (6.7) | 0 (0) | 6 (20.0) | 2 (6.7) |
| SSRI | 0 (0) | 0 (0) | 1 (6.7) | 1 (6.7) | 1 (3.3) | 1 (3.3) |
| AP + benzo | 0 (0) | 1 (6.7) | 0 (0) | 0 (0) | 0 (0) | 1 (3.3) |
| Benzo | 0 (0) | 0 (0) | 1 (6.7) | 0 (0) | 1 (3.3) | 0 (0) |
| Stimulant | 3 (20.0) | 0 (0) | 4 (26.7) | 0 (0) | 7 (23.3) | 0 (0) |
| Alpha2 | 2 (13.3) | 0 (0) | 0 (0) | 0 (0) | 2 (6.7) | 0 (0) |
| Diagnoses (%) | ||||||
| ASD | 11 (73.3) | 11 (73.3) | 22 (73.3) | |||
| ASD only | 7 (46.7) | 8 (53.3) | 15 (50.0) | |||
| ASD + ADHD | 3 (20.0) | 3 (20.0) | 6 (20.0) | |||
| ASD + epilepsy | 1 (6.7) | 0 (0) | 1 (3.3) | |||
| ADHD | 2 (13.3) | 4 (26.7) | 6 (20.0) | |||
| Epilepsy | 2 (13.3) | 0 (0) | 2 (6.7) | |||
Data are mean (SD) or N (%). ADHD, attention deficit hyperactivity disorder; AED, antiepileptic drug; AP, antipsychotics; ASD, autism spectrum disorder; Benzo, benzodiazepine; Prior, medication history up to 8 weeks before trial start; SSRI, selective serotonin reuptake inhibitor; Y, years.